Grant of Options

RNS Number : 2597K

OptiBiotix Health PLC

06 July 2017

 

OptiBiotix Health plc

("OptiBiotix" or the Company")

Grant of Options

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces the grant of options to Per Rehné and Christina Wood, both Directors of the Company at an exercise price of 69.5p. Full details of the options agreement for the relevant parties are set out in the table below.

Per Rehné
Number of Shares under option	500,000
Exercise Price	69.5p
Expiration date	23 June 2027
Interests following grant (shares/options)	500,000 options

Christina Wood
Number of Shares under option	500,000
Exercise Price	69.5p
Expiration date	23 June 2027
Interests following grant (shares/options)	500,000 options

Under the terms of the agreement the options are exercisable on meeting commercial targets including cumulative revenues for each area of director's responsibility.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Per Rehné
2	Reason for notification
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	OptiBiotix Health Plc
b.	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over 500,000 ordinary shares of 2p each ISIN: GB00BP0RTP38
b.	Nature of the transaction	Award of option to purchase ordinary shares of the Company. Following the transaction, Mr Per Rehné has an interest in options 500,000 over ordinary shares.
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			69.5p	500,000
d.	Aggregated information - Aggregated Volume - Price	500,000 69.5p
e.	Date of the transaction	29 June 2017
f.	Place of the transaction	London Stock Exchange, AIM

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Christina Wood
2	Reason for notification
a.	Position/Status	PDMR
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	OptiBiotix Health Plc
b.	LEI	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Options over 500,000 ordinary shares of 2p each ISIN:  GB00BP0RTP38
b.	Nature of the transaction	Award of option to purchase ordinary shares of the Company. Following the transaction, Mrs Christina Wood has an interest in options 500,000 over ordinary shares.
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			69.5p	500,000
d.	Aggregated information - Aggregated Volume - Price	500,000 69.5p
e.	Date of the transaction	29 June 2017
f.	Place of the transaction	London Stock Exchange, AIM

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the grant of options to Commercial Director Per Rehne, and Sales and Marketing Director Christina Wood, who are leading the commercialisation of OptiBiotix's products in global markets. Christina is leading the commercialisation of SlimBiome whilst Per is leading the commercialisation of LP_LDL.. The options are exercisable on achieving a number of cumulative revenue milestones for each area of director's responsibility designed to focus both efforts and activity on rapidly growing revenues." 

For further information, please contact:

OptiBiotix Health plc		www.optibiotix.com
Stephen O'Hara, Chief Executive		Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)		Tel: [phone]
Liam Murray / Jo Turner
finnCap (Broker)		Tel: [phone]
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy		Mob: [phone]

About OptiBiotix - www.optibiotix.com 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

DSHSSWEFIFWSELW